Search company, investor...
CeQur company logo


Founded Year



Series C - II | Alive

Total Raised


Last Raised

$115M | 2 yrs ago

About CeQur

CeQur is developing and commercializing advanced yet simple-to-use insulin delivery devices that make it easier for people living with type 2 diabetes to adhere to therapy and stay in control of their disease. The Company's fully optimized device, PaQ, is a three-day, wearable device that provides freedom from multiple daily insulin injections.

Headquarters Location

Altsagenstrasse 5

Horw, 6048,


+41 41 500 4862

Missing: CeQur's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: CeQur's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Research containing CeQur

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned CeQur in 1 CB Insights research brief, most recently on Oct 28, 2022.

Expert Collections containing CeQur

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

CeQur is included in 5 Expert Collections, including Medical Devices.


Medical Devices

8,875 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



2,119 items


Digital Health

12,620 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)


Health IT

7,901 items

CeQur Patents

CeQur has filed 29 patents.

The 3 most popular patent topics include:

  • Dosage forms
  • Drug delivery devices
  • Insulin therapies
patents chart

Application Date

Grant Date


Related Topics




Pumps, Dosage forms, Drug delivery devices, Fluid dynamics, Insulin therapies


Application Date


Grant Date



Related Topics

Pumps, Dosage forms, Drug delivery devices, Fluid dynamics, Insulin therapies



Latest CeQur News

Global Insulin Pump Market Outlook and Forecast to 2028: Featuring Insulet, Medtronic, Tandem Diabetes Care, CeQur Simplicity and EOFLOW Among Others

Mar 3, 2023

The global insulin pump market size is expected to grow at a CAGR of 8.46% 2022-2028 Market Drivers and Opportunities Technological Advancements Are Revolutionizing the Insulin Delivery The insulin pump market is constantly evolving with new features with technological advancements like the launch of smarter insulin pumps and more connected devices. Most industry players, such as Medtronic, Tandem Diabetes Care, Insulet Corporation, and others, are continuously evolving in technology advancement and new product deliveries in recent years. The explosion in research and development and published studies about the closed-loop system with insulin pumps in diabetes management gives new insulin pump market growth opportunities. Several hybrid systems are expected to be commercialized in the future associated with insulin delivery. In addition to those already available in the market, various systems are expected to be launched. For instance, DBLG1 (Diabeloop, Grenoble, France) received the CE market in European countries for its application in the type 1 diabetes adult patient population. Products like insulin-only iLEt (Beta Bionics, the US) and Omnipod Horizon (Insulet, Billerica, the US) are under clinical trials and are expected to reach the industry in the future. Increasing Diabetes Prevalence & Expenditure Under the overall diabetes population, type 1 diabetes patients are highly dependent on the external support of insulin delivery. These major patient populations significantly propel the insulin pump market growth. In 2021, the estimated prevalence of diabetes among adults 20 - 79 years old increased more than three times, from an estimated 151 million (approximately 4.6% of the global population at the time of 2000) to around 537 million (10.5%) in 2021. Based on that, by 2030, around 643 million population expected to increase. And if the prevalence rate remains the same, it is expected to jump to around 783 million (12.2%) by 2045. Government Initiatives for Diabetes Care Management Rising government initiatives for diabetes care management highly drive insulin pump market growth. Responding to the increasing burden of diabetes worldwide delivers a high demand for care. It positively influenced government initiatives and funding from public and private entities to improve global, regional, and national diabetes health improvements. Based on that, several government and health authorities are making efforts for diabetes care access to comprehensive, equitable, affordable, quality care and medical and technology-based treatments. Available Reimbursement Policies and Healthcare Insurance for Insulin Pump The cost of an insulin pump and associated insulin solutions is comparatively higher than other insulin delivery solutions due to the advancement and additional features associated with the products. However, the available reimbursement policies and healthcare insurance coverage highly support the adoption of insulin pumps. In most countries, these policies favor patients who reduce the cost burden and accelerate the adoption of insulin pumps. These insurances cover the insulin pump and include the insulin pump consumables. This is one of the positive signs that is driving the insulin pump market at a faster rate. Vendor Landscape The global insulin pump market is highly concentrated, with a limited number of players. Various innovative products like patch pumps are being introduced into the market, and the adoption rate is comparatively higher. Tandem Diabetes Care is one of the leading companies in the insulin pump market; estimated that around 750,000 people in the U.S. are currently using an insulin pump. Moreover, the company stated that approximately 450,000 people use insulin pumps in more than 20 countries outside the United States. The company's insulin pump is widely available in the global market. Key Company Profiles

CeQur Frequently Asked Questions (FAQ)

  • When was CeQur founded?

    CeQur was founded in 2008.

  • Where is CeQur's headquarters?

    CeQur's headquarters is located at Altsagenstrasse 5, Horw.

  • What is CeQur's latest funding round?

    CeQur's latest funding round is Series C - II.

  • How much did CeQur raise?

    CeQur raised a total of $271.6M.

  • Who are the investors of CeQur?

    Investors of CeQur include Schroders, Endeavour Vision, VI Partners, Kingdon Capital Management, Credit Suisse Entrepreneur Capital and 9 more.

  • Who are CeQur's competitors?

    Competitors of CeQur include ALung Technologies, Corassist Cardiovascular, Cardiva Medical, SteadyMed Therapeutics, Paragon Medical and 12 more.

Compare CeQur to Competitors

Monterey Devices

Stealth mode medical device company developing devices for drug delivery. Monterey Devices submitted a patent on device for buffering anesthetics.


Portaero, in stealth mode, is a medical devices firm, developing a device for the treatment of COPD (Chronic obstructive pulmonary disease).

Rafael Medical Technologies

Rafael Medical has developed a novel anchoring system for safely implanting and retrieving a wide range of intra-vascular devices in a minimally invasive manner. Based on the technology, diagnostic and therapeutic devices can be delivered into small and large blood vessels alike by way of a small-sized delivery system. Following the completion of the SafeFlo Filter the company is now developing additional devices geared to the interventional cardiology market.


Ovalis was formed by several highly experienced device engineers to develop a set of interventional devices and delivery systems useful for the repair of various cardiovascular defects.

Mercator MedSystems

Mercator MedSystems has developed a broad-based therapeutic platform that allows clinicians to accurately and efficiently deliver drugs and biologics such as stem cells to tissues deep in the body, treating the root cause of significant medical conditions. The company utilizes its family of Micro-Infusion Catheters for targeted treatments via the vascular system, including peripheral artery disease (PAD) and resistant hypertension (HTN); and via the bronchial tree, including malignant airway obstruction secondary to lung cancer. The company's 510(k)-cleared and CE-Marked Cricket and Bullfrog Micro-Infusion Catheters are vascular-access systems that are able to inject drugs, genes, and cells safely through vessel walls into deep tissues without major surgery.

eNeura Therapeutics

eNeura Therapeutics develops the use of portable, non-invasive Transcranial Magnetic Stimulation (TMS) devices for the treatment of migraines.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.